Where does Axim Biotechnologies. Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Axim Biotechnologies. Inc. ranks #23,943 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Axim Biotechnologies. Inc. hold?

Axim Biotechnologies. Inc. holds 11 US utility patents granted between 2017 and 2023, spanning 11 technology areas.

What is Axim Biotechnologies. Inc.'s Innovation Score?

Axim Biotechnologies. Inc. has an Innovation Score of 28.6 out of 100 (28th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Axim Biotechnologies. Inc. focus on?

Axim Biotechnologies. Inc.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 7 patents, ranking #3,032 of 7,163 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

Is Axim Biotechnologies. Inc.'s patent grant rate increasing or decreasing?

Axim Biotechnologies. Inc.'s recent grant velocity is -62% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Axim Biotechnologies. Inc.'s patents?

Axim Biotechnologies. Inc.'s patents average 9.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Axim Biotechnologies. Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Axim Biotechnologies. Inc.

USPTO PatentsView assignee record - 11 granted patents across 11 technology areas, recorded in grant years 2017–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Axim ranks #23,943 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 11 technology areas.

#23,943
of 49,997 US assignees by volume: 28th percentile
by Innovation Score (28.6/100): 9.4
avg claims per patent: -62%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R23943 · US Corporation #23,943 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 11 grants
MID-PACK #23,943/49,997
PHOTO-FINISH Abbott Diagnostics…
CPC-FOCUS A61K · 11 areas
INNOV-THIN 28.6/100
CLAIMS-PAR 9.4 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -62% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Abbott Diagnostics Scarborough, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Axim’s 28.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.6 pts (30%) Velocity 2.7 pts (9%) Breadth 11.7 pts (41%) Claim depth 5.7 pts (20%)

Qualcomm Incorporated · highest

85
Axim Biotechnologies · this assignee

29
3D Lighting… · lowest

7

What this shows Axim's Innovation Score is 28.6/100 (28th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Axim?

Each dot is one of Axim’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Axim’s own 9.4 claims/patent is at or below the 14.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Axim vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Axim's grants concentrate

Axim Biotechnologies. Inc. is a focused PatentsView assignee: 11 CPC subclasses with 63.6% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2019 (4 grants) versus a trough of 1 in 2020. By volume, Axim sits between Avertronics Inc. and Accelerated Ag Technologies, LLC.

Axim's three-year grant acceleration

Axim Biotechnologies. Inc. shows 2 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Avertronics

11
Avic Jonhon Optro…

11
Avox Systems

11
Awol Outdoors

11
AZ

11
Abbott Diagnostic…

11
Abengoa Bioenergy…

11
Accelerated

11
Axim Biotechnolog… ◀

11

What this shows Axim holds 11 patents at rank #23,853, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Axim

By rank, the assignees closest to #23,853 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Axim's primary technology class.

Axim's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 28th percentile higher than 28% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Axim Biotechnologies. Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	2	18.2%
2018	2	18.2%
2019	4	36.4%
2020	1	9.1%
2023	2	18.2%

Which technologies does Axim Biotechnologies. Inc. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 7

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 4

C07D - Heterocyclic Compounds 3

B01D - Separation 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 1

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 1

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 1

A61Q - Specific USE OF Cosmetics OR Similar Toiletry Preparations 1

C07C - Acyclic OR Carbocyclic Compounds 1

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Axim Biotechnologies. Inc.'s patent record in context - here's where to go next.

Axim Biotechnologies. Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 63.6% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #23,943 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Axim Biotechnologies. Inc. against Avertronics Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 28.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.